FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579042246> ?p ?o ?g. }

• W2579042246 abstract "Abstract Abstract 3711 INTRODUCTION: Patients with refractory or relapsed classical Hodgkin Lymphoma (cHL) represent an unmet medical need and would benefit from the development of new therapies. Histone deacetylases (HDACs) and the RAF/MEK/ERK pathway are aberrantly controlled in cHL and influence a broad repertoire of tumor processes, suggesting a rationale for therapeutically targeting these pathways. We targeted these pathways using the HDAC inhibitor Givinostat (Italfarmaco S.p.A., Milan, Italy), and the RAF/MEK/ERK inhibitor Sorafenib (Nexavar, Bayer, Germany, EU) in order to investigate in vitro and in vivo the activity and mechanism(s) of action of this two-drug combination. METHODS: Three cHL cell lines, including HDLM-2, L-540 and HD-MyZ, were used to investigate the effects of Givinostat and Sorafenib, used alone or in combination, by means of in vitro assays evaluating cell growth and cell survival. Additionally, live cell imaging was used to asses the production of reactive oxygen species (ROS), and Western blotting (WB) to assess modulating effects of the two-drug combination on MAPK, PI3K/AKT, HDACs as well as the apoptotic pathways. The efficacy of Givinostat/Sorafenib combination was finally confirmed in NOD/SCID mice with cHL cell line xenografts. RESULTS: While Givinostat and Sorafenib as single agents exerted a limited activity against cHL cells, the combined Givinostat/Sorafenib treatment was associated with potent dephosphorylation of MAPK and PI3K/Akt pathways and significantly increased H3 and H4 acetylation due to a nearly complete inhibition of class I and II HDACs. Furthermore, these events were associated with a time-dependent synergistic cell growth inhibition (70% to 90%) in all Givinostat/Sorafenib-treated cHL cells. Upon Givinostat/Sorafenib exposure, HDLM-2 and L-540 cell lines showed significantly (P ≤.0001) increased levels of apoptosis (90 ± 2% and 96 ± 1%, respectively) and mitochondrial dysfunction (up to 70%, P≤.0001), as compared with single agents. Apoptosis induced by Givinostat/Sorafenib combination failed to induce processing of caspase-8, −9, −3, or cleavage of PARP, and was not reversed by the pan-caspase inhibitor Z-VADfmk, suggesting the occurrence of caspase-independent apoptosis. Besides downregulating the expression of the anti-apoptotic protein Mcl-1 and ERK1/2 phosphorylation, Givinostat/Sorafenib strongly increased expression of the BH-3 only protein Bim, compared to single treatments. These findings were dependent on a potent, early and time-dependent ROS generation (up to 60%, P≤.0001) that was synergistically induced by Givinostat/Sorafenib treatment. Additionally, pretreatment of cHL cells with the ROS inhibitor YCG063 prevented the generation of ROS as well as mitochondrial membrane depolarization along with cell death induced by the two-drug combination, suggesting that ROS generation is the triggering event in Givinostat/Sorafenib induced-cell death. In vivo Givinostat/Sorafenib treatment significantly reduced the growth of L-540 and HD-MyZ nodules, resulting in an average 35% to 65% tumor growth inhibition (P ≤.0001) compared to single treatments, in the absence of any toxicity. Interestingly, as compared to controls or treatment with single agents, the combined Givinostat/Sorafenib treatment significantly increased in vivo Bim expression (7- to 21-fold increase, P ≤.0001), resulting in a marked tumor necrosis (3- to 5-fold increase, P ≤.0001). CONCLUSIONS: The combined Givinostat/Sorafenib treatment demonstrates a potent preclinical in vitro and in vivo activity against cHL cell lines by targeting aberrant expression of HDACs and MAPK. Antitumor activity of this combination involves ROS generation and Bim upregulation and provides a rationale for clinical studies using this combination in refractory/relapsed cHL patients. Disclosures: No relevant conflicts of interest to declare." @default.
• W2579042246 created "2017-01-26" @default.
• W2579042246 creator A5001956192 @default.
• W2579042246 creator A5018731144 @default.
• W2579042246 creator A5030934542 @default.
• W2579042246 creator A5042459008 @default.
• W2579042246 creator A5053689328 @default.
• W2579042246 creator A5064544139 @default.
• W2579042246 creator A5084188322 @default.
• W2579042246 date "2012-11-16" @default.
• W2579042246 modified "2023-09-28" @default.
• W2579042246 title "The histone Deacetylase Inhibitor Givinostat in Combination with Sorafenib Induces Reactive Oxygen Species (ROS) Generation and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts" @default.
• W2579042246 doi "https://doi.org/10.1182/blood.v120.21.3711.3711" @default.
• W2579042246 hasPublicationYear "2012" @default.
• W2579042246 type Work @default.
• W2579042246 sameAs 2579042246 @default.
• W2579042246 citedByCount "0" @default.
• W2579042246 crossrefType "journal-article" @default.
• W2579042246 hasAuthorship W2579042246A5001956192 @default.
• W2579042246 hasAuthorship W2579042246A5018731144 @default.
• W2579042246 hasAuthorship W2579042246A5030934542 @default.
• W2579042246 hasAuthorship W2579042246A5042459008 @default.
• W2579042246 hasAuthorship W2579042246A5053689328 @default.
• W2579042246 hasAuthorship W2579042246A5064544139 @default.
• W2579042246 hasAuthorship W2579042246A5084188322 @default.
• W2579042246 hasConcept C104317684 @default.
• W2579042246 hasConcept C190283241 @default.
• W2579042246 hasConcept C2776202225 @default.
• W2579042246 hasConcept C2778019345 @default.
• W2579042246 hasConcept C2778305200 @default.
• W2579042246 hasConcept C2778695046 @default.
• W2579042246 hasConcept C2781462825 @default.
• W2579042246 hasConcept C502942594 @default.
• W2579042246 hasConcept C55493867 @default.
• W2579042246 hasConcept C57074206 @default.
• W2579042246 hasConcept C62478195 @default.
• W2579042246 hasConcept C64927066 @default.
• W2579042246 hasConcept C75217442 @default.
• W2579042246 hasConcept C86554907 @default.
• W2579042246 hasConcept C86803240 @default.
• W2579042246 hasConcept C98274493 @default.
• W2579042246 hasConceptScore W2579042246C104317684 @default.
• W2579042246 hasConceptScore W2579042246C190283241 @default.
• W2579042246 hasConceptScore W2579042246C2776202225 @default.
• W2579042246 hasConceptScore W2579042246C2778019345 @default.
• W2579042246 hasConceptScore W2579042246C2778305200 @default.
• W2579042246 hasConceptScore W2579042246C2778695046 @default.
• W2579042246 hasConceptScore W2579042246C2781462825 @default.
• W2579042246 hasConceptScore W2579042246C502942594 @default.
• W2579042246 hasConceptScore W2579042246C55493867 @default.
• W2579042246 hasConceptScore W2579042246C57074206 @default.
• W2579042246 hasConceptScore W2579042246C62478195 @default.
• W2579042246 hasConceptScore W2579042246C64927066 @default.
• W2579042246 hasConceptScore W2579042246C75217442 @default.
• W2579042246 hasConceptScore W2579042246C86554907 @default.
• W2579042246 hasConceptScore W2579042246C86803240 @default.
• W2579042246 hasConceptScore W2579042246C98274493 @default.
• W2579042246 hasLocation W25790422461 @default.
• W2579042246 hasOpenAccess W2579042246 @default.
• W2579042246 hasPrimaryLocation W25790422461 @default.
• W2579042246 hasRelatedWork W103874930 @default.
• W2579042246 hasRelatedWork W1626821504 @default.
• W2579042246 hasRelatedWork W1966248219 @default.
• W2579042246 hasRelatedWork W1984609113 @default.
• W2579042246 hasRelatedWork W2015462356 @default.
• W2579042246 hasRelatedWork W2018385940 @default.
• W2579042246 hasRelatedWork W2055695980 @default.
• W2579042246 hasRelatedWork W2071361048 @default.
• W2579042246 hasRelatedWork W2071548786 @default.
• W2579042246 hasRelatedWork W2132465832 @default.
• W2579042246 hasRelatedWork W2170168836 @default.
• W2579042246 hasRelatedWork W2172592582 @default.
• W2579042246 hasRelatedWork W2313783489 @default.
• W2579042246 hasRelatedWork W2344221789 @default.
• W2579042246 hasRelatedWork W2559998322 @default.
• W2579042246 hasRelatedWork W2589915279 @default.
• W2579042246 hasRelatedWork W2614166919 @default.
• W2579042246 hasRelatedWork W2967362211 @default.
• W2579042246 hasRelatedWork W2979572678 @default.
• W2579042246 hasRelatedWork W3033753822 @default.
• W2579042246 isParatext "false" @default.
• W2579042246 isRetracted "false" @default.
• W2579042246 magId "2579042246" @default.
• W2579042246 workType "article" @default.